ARCHIVES

Perifosine Increases PFS In Phase II Study

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

Environmental Emphasis Urged, Including New Role For Comp Centers NCAB Unenthusiastic

March 21, 1975

Patients “Raise A Voice” For Provenge Approval.

April 27, 2007

In Brief: ACS Massachusetts Div. Offers $1,500 Grants To Improve community Hospital Cancer Care

March 2, 1979

Local University Competing for Part FCRF Contract

December 4, 1981

Leyland-Jones Named Director of Emory’s Winship Cancer Institute

November 17, 2006